Insulet Corporation’s RM878 Million Insulin Plant

Skrine assisted Insulet Corporation in the legal aspects of establishing their Malaysian operations.

Tubeless insulin pump technology firm Insulet Corporation announced its new manufacturing facility in Johor Baru, to produce its Omnipod® Insulin Management System.

The new manufacturing facility will include approximately 400,000 square feet of manufacturing space. Insulet plans to invest approximately RM800 million over five years and hire more than 500 full-time employees once the facility is operating at full capacity.

The architectural design includes sustainable elements that qualify for Green Building Initiative (GBI) and Leadership in Energy and Environmental Design (LEED) certification.

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform.

The Skrine team consisted of Fariz Abdul Aziz (Picture), Jesy Ooi, Shannon Rajan, Jillian Chia, Richard Khoo, Selvamalar Alagaratnam, and supported by Senior Associates, Manshan Singh, Tan Wei Xian and Rachel Chiah, and Associates, Jeremiah Ch’ng, Raaasi Laarnia, Jemima Tang and Vanessa Ho.

Involved fees earner: Vanessa Ho Pei Wei – Skrine; Selvamalar Alagaratnam – Skrine; Fariz Abdul Aziz – Skrine; Jillian Chia – Skrine; Rachel Chiah – Skrine; Jeremiah Ch’ng Khoo Ern – Skrine; Richard Khoo Boo Hin – Skrine; Jesy Ooi – Skrine; Shannon Rajan – Skrine; Raaasi Laarnia Rajandran – Skrine; Manshan Singh – Skrine; Jemima Tang – Skrine; Tan Wei Xian – Skrine;

Law Firms: Skrine;

Clients: Insulet Corporation;

Sonia Carcano

Author: Sonia Carcano